Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy
Milind Y. Desai(Cleveland Clinic), Anjali Owens(University of Pennsylvania), Olga Azevedo(British Heart Foundation), Roberto Barriales‐Villa, Perry Elliott(UCL Australia), Esther Zorio(Hospital Universitari i Politècnic La Fe), Michael Arad(Tel Aviv University), Iacopo Olivotto, Hiroaki Kitaoka(University of Kochi), Benjamin Meder(Heidelberg University), Steven E. Nissen(Cleveland Clinic), Ron Aronson(Bristol-Myers Squibb (United States)), Victoria Florea(Bristol-Myers Squibb (United States)), Nicolas Verheyen(Medical University of Graz), Edileide de Barros Correia(Instituto Dante Pazzanese de Cardiologia), Pablo García‐Pavía(Universidad Francisco de Vitoria), Renato D. Lópes(Duke University), Kathy Wolski(Cleveland Clinic), Qiuqing Wang(Cleveland Clinic), Bharat Suryawanshi(Bristol-Myers Squibb (United States)), Sung‐Hee Shin(Inha University Hospital), Fábio Fernandes(University of Illinois Chicago), Zhaoqing Wang(Bristol-Myers Squibb (United States)), Theodore P. Abraham(University of California, San Francisco)
Cited by 11
Related Papers
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
|New England Journal of Medicine|2007|4.7k
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2013|3.4k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease
|European Heart Journal|2020|1.8k